Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Absci Corporation is engaged in the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions. These actions are both assigned to 1 distinct art unit. Prosecution involves 2 distinct examiners. GANAPATHIRAM RAGHU is the busiest examiner, responsible for 1 pending action.
Having the 2 distinct examiners for the 2 pending actions within the 1 distinct art unit suggests that the company's Biotechnology & Pharmaceuticals filings are being reviewed by different individuals despite the technical concentration. This distribution prevents a single examiner from controlling the entire pending portfolio.
The involvement of the distinct examiners for the pending actions means that each case is receiving an independent review. Practitioners should be prepared for different examiner perspectives within the same art unit. This structure provides the company with a more diverse set of feedback on its current Biotechnology & Pharmaceuticals filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAGHU, GANAPATHIRAM | 1 | 73.7% | +26.5% |
| YU, TIAN NMN | 1 | 55.6% | +19.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724015 | KNOCKOUT OF ptsP GENE ELEVATES ACTIVE GENE EXPRESSION | RAGHU, GANAPATHIRAM | — |
| 18606513 | COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS | YU, TIAN NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724015 | KNOCKOUT OF ptsP GENE ELEVATES ACTIVE GENE EXPRESSION | RAGHU, GANAPATHIRAM | — |
| 18606513 | COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS | YU, TIAN NMN | — |
| Art Unit | Apps |
|---|---|
| 1656 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724015 | KNOCKOUT OF ptsP GENE ELEVATES ACTIVE GENE EXPRESSION | RAGHU, GANAPATHIRAM | 1656 | §102§103§112 | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18606513 | COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS | YU, TIAN NMN | 1656 | §102§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAbsci Corporation has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Ganapathiram Raghu has the most, with 1 of Absci Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
